Jaime L Rubin
Overview
Explore the profile of Jaime L Rubin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merlo C, Thorat T, McGarry L, Scirica C, DerSarkissian M, Nguyen C, et al.
Pulm Ther
. 2024 Sep;
10(4):483-494.
PMID: 39266929
Introduction: Ivacaftor (IVA) has been shown to change the trajectory of cystic fibrosis (CF) disease progression by slowing the rate of lung function decline in clinical studies. Long-term real-world data...
2.
Merlo C, Thorat T, DerSarkissian M, McGarry L, Nguyen C, Gu Y, et al.
Thorax
. 2024 Jun;
79(10):925-933.
PMID: 38937105
Background: Ivacaftor (IVA) has been shown to improve lung function and other clinical outcomes in people with cystic fibrosis (CF). A decade of real-world IVA availability has enabled the examination...
3.
Merlo C, McGarry L, Thorat T, Nguyen C, DerSarkissian M, Muthukumar A, et al.
Thorax
. 2024 May;
79(10):915-924.
PMID: 38719441
Background: Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier versus later ages has not been...
4.
5.
McGarry L, Bhaiwala Z, Lopez A, Chandler C, Pelligra C, Rubin J, et al.
PLoS One
. 2023 Apr;
18(4):e0283479.
PMID: 37043485
Objectives: Cystic fibrosis (CF) is a rare genetic disease characterized by life-shortening lung function decline. Ivacaftor, a CF transmembrane conductance regulator modulator (CFTRm), was approved in 2012 for people with...
6.
Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin J
J Cyst Fibros
. 2023 Feb;
22(4):607-614.
PMID: 36849331
Background: A series of phase 3 clinical trials have demonstrated that elexacaftor plus tezacaftor plus ivacaftor (ELX/TEZ/IVA) is safe and efficacious in people with cystic fibrosis (pwCF) aged ≥12 years...
7.
Rubin J, Lopez A, Booth J, Gunther P, Jena A
J Med Econ
. 2022 May;
25(1):783-791.
PMID: 35549639
Objectives: Cost-effectiveness analysis (CEA) is useful to assess the value of health care interventions based on clinical effectiveness and costs. However, standard CEA methods make important assumptions that may significantly...
8.
Thorat T, McGarry L, Bonafede M, Limone B, Rubin J, Jariwala-Parikh K, et al.
Pediatr Pulmonol
. 2021 Jun;
56(9):2833-2844.
PMID: 34138523
Background: Adverse health impacts of cystic fibrosis (CF) can be present in children before respiratory complications are observed. Children with CF show progressive health decline, with increasing lung function decline...
9.
Flume P, Fischer Biner R, Downey D, Brown C, Jain M, Fischer R, et al.
Lancet Respir Med
. 2021 Feb;
9(7):733-746.
PMID: 33581080
Background: Tezacaftor-ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8-24 weeks in phase 3 clinical studies...
10.
Rubin J, OCallaghan L, Pelligra C, Konstan M, Ward A, Ishak J, et al.
Ther Adv Respir Dis
. 2019 Feb;
13:1753466618820186.
PMID: 30803355
Background: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of lumacaftor/ivacaftor...